MWNA
CNTA

Marshall Wace North America’s Centessa Pharmaceuticals CNTA Stock Holding History

Marshall Wace North America’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,228
Closed -$760K – 1468
2021
Q2 		$760K Buy
+34,228
New +$804K ﹤0.01% 1084

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Marshall Wace North America's CNTA Position: Q3 2021 in Review

Marshall Wace North America sold out of Centessa Pharmaceuticals (CNTA) in Q3 2021, closing a stake of 34,228 shares — an estimated $760K sold.

Marshall Wace North America first reported a position in CNTA in Q2 2021 and held it in 1 quarter. The position peaked at $760K in Q2 2021. 40 funds tracked by Wall St. Rank hold CNTA as of Q3 2021.

  • Marshall Wace North America reported no remaining Centessa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 34,228 Centessa Pharmaceuticals shares in Q3 2021, an estimated $760K.
  • Marshall Wace North America first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Centessa Pharmaceuticals position peaked at $760K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.